Lecanemab for cognitive dysfunction

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 25 Mar 2019: Trial registered, NCT03887455
  2. 27 Mar 2019: Trial started, NCT03887455

The trials

NCT02094729: A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

State
Completed
Phase
Phase 1
People
26 taking part
Started
Sep 2013
Primary completion
Mar 2015
Arms
BAN2401 2.5 mg/kg, BAN2401 5 mg/kg, BAN2401 10 mg/kg
Results
None posted
  1. 24 Mar 2014: Trial registered

NCT03887455: A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

State
Under way
Phase
Phase 3
People
1,906 taking part
Started
27 Mar 2019
Primary completion
31 Dec 2026
Arms
Core Study: Lecanemab 10 milligram per kilogram (mg/kg) biweekly, Extension Phase: Lecanemab 10 mg/kg biweekly, Extension Phase: Lecanemab Subcutaneous (SC) Injection Dose 1, Extension Phase: Lecanemab SC Injection Dose 2, Extension Phase: Lecanemab SC Injection Dose 3, Extension Phase: Lecanemab SC Injection Dose 4, Extension Phase: Lecanemab 10 mg/kg IV Infusion Once Every 4 Weeks (Q4W), Extension Phase B
Results
None posted
  1. 25 Mar 2019: Trial registered
  2. 27 Mar 2019: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as BAN2401 10 mg/kg, BAN2401 2.5 mg/kg, BAN2401 5 mg/kg, Lecanemab 10 mg/kg, Lecanemab 2.5 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab IV, Lecanemab SC.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.